Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

v3.24.3
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Operating expenses:        
Research and development $ 2,563,774 $ 1,142,160 $ 6,313,373 $ 5,658,127
General and administrative 1,870,903 1,375,380 4,511,660 4,729,969
Total operating expenses 4,434,677 2,517,540 10,825,033 10,388,096
Loss from operations (4,434,677) (2,517,540) (10,825,033) (10,388,096)
Other income (expense):        
Change in fair value of financial instruments 16,969,126 119,019 17,014,080 683,568
Interest expense   (75,413) (76,775) (124,595)
Other income 235,912 113,286 399,344 197,070
Loss on issuance of common shares, warrants, and pre-funded warrants in July 2024 PIPE (3,494,536)   (3,494,536)  
Total other income (expense), net 13,710,502 156,892 13,842,113 756,043
Net income (loss) 9,275,825 (2,360,648) 3,017,080 (9,632,053)
Other comprehensive income (loss)        
Foreign currency translation adjustment       (175,815)
Comprehensive income (loss) $ 9,275,825 $ (2,360,648) $ 3,017,080 $ (9,807,868)
Net income (loss) per share, basic $ 0.31 $ (0.19) $ 0.13 $ (0.98)
Net income (loss) per share, diluted $ 0.31 $ (0.19) $ 0.13 $ (0.98)
Weighted-average shares outstanding of common shares, basic 30,023,675 12,370,830 22,953,751 9,861,719
Weighted-average shares outstanding of common shares, diluted 30,067,095 12,370,830 23,676,104 9,861,719